Literature DB >> 35947166

Psychopharmacological properties and therapeutic profile of the antidepressant venlafaxine.

Claire Rampon1, Bruno P Guiard2, Basile Coutens1, Antoine Yrondi3.   

Abstract

Major depression (MD) is one of the most common psychiatric disorders worldwide. Currently, the first-line treatment for MD targets the serotonin system but these drugs, notably the selective serotonin reuptake inhibitors, usually need 4 to 6 weeks before the benefit is felt and a significant proportion of patients shows an unsatisfactory response. Numerous treatments have been developed to circumvent these issues as venlafaxine, a mixed serotonin-norepinephrine reuptake inhibitor that binds and blocks both the SERT and NET transporters. Despite this pharmacological profile, it is difficult to have a valuable insight into its ability to produce more robust efficacy than single-acting agents. In this review, we provide an in-depth characterization of the pharmacological properties of venlafaxine from in vitro data to preclinical and clinical efficacy in depressed patients and animal models of depression to propose an indirect comparison with the most common antidepressants. Preclinical studies show that the antidepressant effect of venlafaxine is often associated with an enhancement of serotonergic neurotransmission at low doses. High doses of venlafaxine, which elicit a concomitant increase in 5-HT and NE tone, is associated with changes in different forms of plasticity in discrete brain areas. In particular, the hippocampus appears to play a crucial role in venlafaxine-mediated antidepressant effects notably by regulating processes such as adult hippocampal neurogenesis or the excitatory/inhibitory balance. Overall, depending on the dose used, venlafaxine shows a high efficacy on depressive-like symptoms in relevant animal models but to the same extent as common antidepressants. However, these data are counterbalanced by a lower tolerance. In conclusion, venlafaxine appears to be one of the most effective treatments for treatment of major depression. Still, direct comparative studies are warranted to provide definitive conclusions about its superiority.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  5-HT; Antidepressants; Major depression disorder; NE; Venlafaxine

Mesh:

Substances:

Year:  2022        PMID: 35947166     DOI: 10.1007/s00213-022-06203-8

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.415


  122 in total

1.  Venlafaxine protects against stress-induced oxidative DNA damage in hippocampus during antidepressant testing in mice.

Authors:  Basel A Abdel-Wahab; Ragaa H Salama
Journal:  Pharmacol Biochem Behav       Date:  2011-07-29       Impact factor: 3.533

2.  Venlafaxine stimulates PNN proteolysis and MMP-9-dependent enhancement of gamma power; relevance to antidepressant efficacy.

Authors:  Seham Alaiyed; P Lorenzo Bozzelli; Adam Caccavano; Jian Young Wu; Katherine Conant
Journal:  J Neurochem       Date:  2019-02-20       Impact factor: 5.372

3.  [Possible serotonin syndrome associated with administration of venlafaxine and tramadol].

Authors:  M S Albiñana Pérez; L Cea Pereira; J Bilbao Salcedo; I Rodríguez Penín
Journal:  Farm Hosp       Date:  2012 Nov-Dec

4.  Organic cation transporter 2 controls brain norepinephrine and serotonin clearance and antidepressant response.

Authors:  A Bacq; L Balasse; G Biala; B Guiard; A M Gardier; A Schinkel; F Louis; V Vialou; M-P Martres; C Chevarin; M Hamon; B Giros; S Gautron
Journal:  Mol Psychiatry       Date:  2011-07-19       Impact factor: 15.992

5.  Shifts in excitatory/inhibitory balance by juvenile stress: A role for neuron-astrocyte interaction in the dentate gyrus.

Authors:  Anne Albrecht; Sebastian Ivens; Ismini E Papageorgiou; Gürsel Çalışkan; Nasrin Saiepour; Wolfgang Brück; Gal Richter-Levin; Uwe Heinemann; Oliver Stork
Journal:  Glia       Date:  2016-02-15       Impact factor: 7.452

6.  Preclinical pharmacology of F-98214-TA, a novel potent serotonin and norepinephrine uptake inhibitor with antidepressant and anxiolytic properties.

Authors:  Inés Artaiz; Arturo Zazpe; Ana Innerárity; Elena Del Olmo; Alvaro Díaz; José Angel Ruiz-Ortega; Elena Castro; Ruth Pena; Luis Labeaga; Angel Pazos; Aurelio Orjales
Journal:  Psychopharmacology (Berl)       Date:  2005-10-19       Impact factor: 4.530

Review 7.  Neurobiological bases for the relation between sleep and depression.

Authors:  Joëlle Adrien
Journal:  Sleep Med Rev       Date:  2002-10       Impact factor: 11.609

8.  Levomilnacipran (F2695), a norepinephrine-preferring SNRI: profile in vitro and in models of depression and anxiety.

Authors:  A L Auclair; J C Martel; M B Assié; L Bardin; P Heusler; D Cussac; M Marien; A Newman-Tancredi; J A O'Connor; R Depoortère
Journal:  Neuropharmacology       Date:  2013-03-13       Impact factor: 5.250

9.  Venlafaxine Stimulates an MMP-9-Dependent Increase in Excitatory/Inhibitory Balance in a Stress Model of Depression.

Authors:  Seham Alaiyed; Mondona McCann; Gouri Mahajan; Grazyna Rajkowska; Craig A Stockmeier; Kenneth J Kellar; Jian Young Wu; Katherine Conant
Journal:  J Neurosci       Date:  2020-04-08       Impact factor: 6.167

10.  Insight into the metabolic mechanism of Diterpene Ginkgolides on antidepressant effects for attenuating behavioural deficits compared with venlafaxine.

Authors:  Shunjie Bai; Xiaodong Zhang; Zhi Chen; Wei Wang; Qingchuan Hu; Zihong Liang; Peng Shen; Siwen Gui; Li Zeng; Zhao Liu; Jianjun Chen; Xiongfei Xie; Hua Huang; Yu Han; Haiyang Wang; Peng Xie
Journal:  Sci Rep       Date:  2017-08-29       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.